Tag results:
cancer stem cells
Mammary Cell News
New Advances in Targeted Therapy of HER2-Negative Breast Cancer
[Frontiers in Oncology] The authors describe the potential targets that may be used for breast cancer treatment from the aspects of PI3K/AKT signaling pathway, DDR, angiogenesis, the cell cycle, breast cancer stem cells, etc
Neural Cell News
HNF4A-AS1-Encoded Small Peptide Promotes Self-Renewal and Aggressiveness of Neuroblastoma Stem Cells via eEF1A1-Repressed SMAD4 Transactivation
[Oncogene] The authors suggested that hepatocyte nuclear factor 4 alpha antisense RNA 1 (HNF4A-AS1)-encoded small 51-amino acid peptide promoted self-renewal and aggressive features of neuroblastoma stem cells by eEF1A1-repressed SMAD family member 4 (SMAD4) transactivation.
Cancer Stem Cell News
UPF1 Contributes to the Maintenance of Endometrial Cancer Stem Cell Phenotype by Stabilizing LINC00963
[Cell Death & Disease] Scientists showed that the expression of UPF1 was upregulated in endometrial cancer tissues and endometrial cancer stem cells and correlated with poor clinicopathological characteristics.
ESC & iPSC News
StemSC: A Cross-Dataset Human Stemness Index for Single-Cell Samples
[Stem Cell Research & Therapy] Researchers constructed a stemness index for single-cell samples (StemSC) based on relative expression orderings of gene pairs.
Mammary Cell News
A Novel HIF-2α Targeted Inhibitor Suppresses Hypoxia-Induced Breast Cancer Stemness via SOD2-mtROS-PDI/GPR78-UPRER Axis
[Cell Death & Differentiation] Investigators illustrated that HIF-2α induced stemness in breast cancers under hypoxia through the SOD2-mtROS-PDI/GRP78-UPRER pathway, linking mitochondrial metabolic state to endoplasmic reticulum response via mitochondrial reactive oxygen species (mtROS) level.
Cancer Stem Cell News
LCOR Mediates Interferon-Independent Tumor Immunogenicity and Responsiveness to Immune-Checkpoint Blockade in Triple-Negative Breast Cancer
[Nature Cancer] Researchers showed that immune-checkpoint blockade (ICB) therapy selects for ligand-dependent corepressor (LCOR)low CSCs with reduced antigen processing/presentation machinery driving immune escape and ICB resistance in triple-negative breast cancer.